By Sabela Ojea

BioMarin Pharmaceutical said the Food and Drug Administration has approved its new drug application to treat all pediatric patients with a growth condition.

The biotechnology company on Friday said its Voxzogo treatment is aimed at increasing linear growth and has been approved based on an improvement in annualized growth velocity.

The medication had previously been indicated for achondroplasia patients who were 5 years of age and older.

Voxzogo is currently approved in Europe for children with achondroplasi who are at least 2 years old.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 20, 2023 16:39 ET (20:39 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos BioMarin Pharmaceutical.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos BioMarin Pharmaceutical.